Published Papers by IgAN Investigators

Antonio Amoroso, MD
  1. Roccatello D, Coppo R, Piccoli G, Cordonnier D, Martina G, Rollino C, Picciotto G, Sena LM, Amoroso A.Circulating Fc-receptor blocking factors in IgA nephropathies.ClinNephrol. 1985 Apr;23(4):159-68.
  2. Coppo R, Amore A, Roccatello D, Amoroso A, Maffei S, Quattrocchio G, Molino A, Gianoglio B, Piccoli G.Complement receptor (CR1) and IgG or IgA on erythrocytes and in circulating immune complexes in patients with glomerulonephritis.Nephrol Dial Transplant. 1989;4(11):932-8.
  3. Amoroso A, Stella I, Pietrucci A, Ferri GM.[Glomerulonephritis with mesangial deposition of IgA].RecentiProg Med. 1989 Mar;80(3):170-5. Review. Italian.
  4. Roccatello D, Picciotto G, Coppo R, Piccoli G, Molino A, Cacace G, Amore A, Amoroso A, Quattrocchio G, Sena LM.Clearance of polymeric IgA aggregates in humans. Am J Kidney Dis. 1989 Nov;14(5):354-60.
  5. 5. Scolari F, Scaini P, Savoldi S, Prati E, Sacchi G, Amoroso A, Mazzola G, Canale L, Borelli I, Cristinelli L, et al.Familial IgMmesangial nephropathy: a morphologic and immunogenetic study of three pedigrees. Am J Nephrol. 1990;10(4):261-8.
  6. Coppo R, Roccatello D, Amore A, Quattrocchio G, Molino A, Gianoglio B, Amoroso A, Bajardi P, Piccoli G.Effects of a gluten-free diet in primary IgA nephropathy.ClinNephrol. 1990 Feb;33(2):72-86.
  7. Roccatello D, Picciotto G, Ropolo R, Coppo R, Quattrocchio G, Cacace G, Molino A, Amoroso A, Baccega M, Isidoro C, et al. Kinetics and fate of IgA-IgG aggregates as a model of naturally occurring immune complexes in IgA nephropathy. Lab Invest. 1992 Jan;66(1):86-95.
  8. Rollino C, Roccatello D, Mazzucco G, Boccadoro M, Massaia M, Battaglio S, Omedé P, Amoroso A, Mazzola G, Aimo G, et al.Immunologic characteristics of fibrillary glomerulonephritis. Nephron. 1992;62(4):399-403.
  9. Scolari F, Amoroso A, Savoldi S, Prati E, Scaini P, Manganoni A, Borelli I, Mazzola G, Canale L, Sacchi G, et al.Familial occurrence of primary glomerulonephritis: evidence for a role of genetic factors.Nephrol Dial Transplant. 1992;7(7):587-96.
  10. Afeltra A, Paggi A, Ferri GM, Amoroso A, Di Prima MA, Startari S, Faralli AR, Bonomo L.CD5+ B lymphocytes and CD4+ CD45RA+ T cells in Graves' disease.Endocr Res. 1993 Mar;19(1):73-85.
  11. Amoroso A, Danek G, Vatta S, Crovella S, Berrino M, Guarrera S, Fasano ME, Mazzola G, Amore A, Gianoglio B, Peruzzi L, Coppo R.Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schoenlein patients. Italian Group of Renal Immunopathology.Nephrol Dial Transplant. 1998 Dec;13(12):3184-8.
  12. Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, Viola BF, Nicola B, Movilli E, Sandrini M, Campanini M, Maiorca R.Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. 1999 May;33(5):857-65.
  13. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP.IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  14. Pirulli D, Boniotto M, Vatta L, Crovella S, Spano A, Morgutti M, Zezlina S, Bertola L, Roccatello D, Scolari F, Peruzzi L, Savoldi S, Amoroso A.Polymorphisms in the promoter region and at codon 54 of the MBL2 gene are not associated with IgA nephropathy.Nephrol Dial Transplant. 2001 Apr;16(4):759-64.
  15. Trevisiol C, Ventura A, Baldas V, Tommasini A, Santon D, Martelossi S, Torre G, Berti I, Spanò A, Crovella S, Amoroso A, Sblattero D, Marzari R, Bradbury A, Not T. A reliable screening procedure for coeliac disease in clinical practice.Scand J Gastroenterol. 2002 Jun;37(6):679-84.
  16. Caccavo D, Rigon A, Picardi A, Galluzzo S, Vadacca M, Ferri GM, Amoroso A, Afeltra A.Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.ClinRheumatol. 2005 Aug;24(4):381-7. Epub 2004 Dec 9.
  17. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frascà GM; European IgA nephropathy Consortium.The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  18. Bisceglia L, Cerullo G, Forabosco P, Torres DD, Scolari F, Di Perna M, Foramitti M, Amoroso A, Bertok S, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Ermelinda M, Zelante L, Schena FP; European IgAN Consortium. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci.Am J Hum Genet. 2006 Dec;79(6):1130-4. Epub 2006 Nov
  19. Di Duca M, Oleggini R, Sanna-Cherchi S, Pasquali L, Di Donato A, Parodi S, Bertelli R, Caridi G, Frasca G, Cerullo G, Amoroso A, Schena FP, Scolari F, Ghiggeri GM; European IgA Nephropathy Consortium. Cis and trans regulatory elements in NPHS2 promoter: implications in proteinuria and progression of renal diseases. Kidney Int. 2006 Oct;70(7):1332-41. Epub 2006 Aug 9.
  20. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frascà G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F.IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006 May;47(5):761-9.
  21. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study.Eur J Hum Genet. 2006 Apr;14(4):488-96.
  22. Schena FP, Cerullo G, Torres DD, Zaza G, Cox S, Bisceglia L, Scolari F, Frascá G, Ghiggeri GM, Amoroso A; European IgA Nephropathy Consortium. Searching for IgA nephropathy candidate genes: genetic studies combined with high throughput innovative investigations.ContribNephrol. 2007;157:80-9. Review.
  23. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A; European IgAN Consortium.Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009 Jan-Feb;22(1):152-9.
  24. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011 Mar 13;43(4):321-7.
Efstathios Alexopoulos, MD
  1. Alexopoulos E, Seron D, Hartley RB, Nolasco F, Cameron JS. The role of interstitial infiltrates in IgA nephropathy: a study with monoclonal antibodies. Nephrol Dial Transplant. 1989;4(3):187-95.
  2. Alexopoulos E, Papaghianni A, Papadimitriou M. The pathogenetic significance of C5b-9 in IgA nephropathy. Nephrol Dial Transplant. 1995;10(7):1166-72.
  3. Alexopoulos E. Treatment of primary IgA nephropathy. Kidney Int. 2004 Jan;65(1):341-55.
  4. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen. Ren Fail. 2004 Jul;26(4):453-9.
  5. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frascà GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  6. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
  7. Bisceglia L, Cerullo G, Forabosco P, Torres DD, Scolari F, Di Perna M, Foramitti M, Amoroso A, Bertok S, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Ermelinda M, Zelante L, Schena FP; European IgAN Consortium. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006 Dec;79(6):1130-4. Epub 2006 Nov 3.
  8. Stangou M, Alexopoulos E, Papagianni A, Pantzaki A, Bantis C, Dovas S, Economidou D, Leontsini M, Memmos D. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology (Carlton). 2009 Sep;14(6):613-20. Epub 2009 Jan 8.
  9. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A; European IgAN Consortium. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009 Jan-Feb;22(1):152-9.
  10. Stangou M, Alexopoulos E, Pantzaki A, Leonstini M, Memmos D. C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol. 2008;42(4):373-80.
  11. Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, Ivens K, Heering PJ. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis. 2010 Feb;55(2):259-68. Epub 2009 Dec 30.
  12. Stangou M, Ekonomidou D, Giamalis P, Liakou H, Tsiantoulas A, Pantzaki A, Papagianni A, Efstratiadis G, Alexopoulos E, Memmos D. Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol. 2011 Jun;15(3):373-80. Epub 2011 Feb 8.
Jurgen Floege, MD
  1. Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 1991 Sep;40(3):477-88.
  2. Yoshimura A, Gordon K, Alpers CE, Floege J, Pritzl P, Ross R, Couser WG, Bowen-Pope DF, Johnson RJ. Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney Int. 1991 Sep;40(3):470-6.
  3. Johnson R, Iida H, Yoshimura A, Floege J, Bowen-Pope DF. Platelet-derived growth factor: a potentially important cytokine in glomerular disease. Kidney Int. 1992 Mar;41(3):590-4.
  4. Johnson RJ, Floege J, Couser WG, Alpers CE. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol. 1993 Aug;4(2):119-28. Erratum in: J Am Soc Nephrol 1993 Nov;4(5):1237.
  5. Johnson RJ, Lombardi D, Eng E, Gordon K, Alpers CE, Pritzl P, Floege J, Young B, Pippin J, Couser WG, et al. Modulation of experimental mesangial proliferative nephritis by interferon-gamma. Kidney Int. 1995 Jan;47(1):62-9.
  6. Zwirner J, Burg M, Schulze M, Brunkhorst R, Gotze O, Koch KM, Floege J. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 1997 Apr;51(4):1257-64.
  7. Burg M, Ostendorf T, Mooney A, Koch KM, Floege J. Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety. Lab Invest. 1997 Apr;76(4):505-16.
  8. Ohmacht C, Kliem V, Burg M, Nashan B, Schlitt HJ, Brunkhorst R, Koch KM, Floege J. Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation. 1997 Nov 27;64(10):1493-6.
  9. Floege J, Burg M, Hugo C, Gordon KL, Van Goor H, Reidy M, Couser WG, Koch KM, Johnson RJ. Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 1998 May;9(5):792-801.
  10. Floege J, Burg M, Kliem V. Recurrent IgA nephropathy after kidney transplantation: not a benign condition. Nephrol Dial Transplant. 1998 Aug;13(8):1933-5.
  11. Floege J. New diagnostic and therapeutic aspects in IgA nephropathy. Kidney Blood Press Res. 1998;21(2-4):283-5.
  12. Floege J. The immunopathogenesis of IgA-nephropathy. Przegl Lek. 1998;55 Suppl 1:19-21.
  13. Floege J, Mertens P. Therapy of patients with IgA-nephropathy: a critical appraisal. Kidney Blood Press Res. 2000;23(3-5):207-9.
  14. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol. 2000 Dec;11(12):2395-403.
  15. Ostendorf T, Kunter U, Grone HJ, Bahlmann F, Kawachi H, Shimizu F, Koch KM, Janjic N, Floege J. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2001 May;12(5):909-18.
  16. Westenfeld R, Gawlik A, de Heer E, Kitahara M, Abou-Rebyeh F, Floege J, Ketteler M. Selective inhibition of inducible nitric oxide synthase enhances intraglomerular coagulation in chronic anti-Thy 1 nephritis. Kidney Int. 2002 Mar;61(3):834-8.
  17. Ostendorf T, Kunter U, van Roeyen C, Dooley S, Janjic N, Ruckman J, Eitner F, Floege J. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol. 2002 Mar;13(3):658-67.
  18. Gaertner SA, Janssen U, Ostendorf T, Koch KM, Floege J, Gwinner W. Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2002 Dec;13(12):2930-7.
  19. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant. 2003 Feb;18(2):241-5.
  20. Eitner F, Ostendorf T, Kretzler M, Cohen CD, Eriksson U, Grone HJ, Floege J; ERCB-Consortium. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol. 2003 May;14(5):1145-53.
  21. Janssen U, Eitner F, Kunter U, Ostendorf T, Wolf G, Chaponnier C, Gabbiani G, Kerjaschki D, Floege J. Extracellular actin impairs glomerular capillary repair in experimental mesangioproliferative glomerulonephritis. Nephron Exp Nephrol. 2003;93(4):e158-67.
  22. Mertens PR, Floege J. [IgA-nephropathy: the most common type of glomerulonephritis] Dtsch Med Wochenschr. 2003 May 30;128(22):1242-6.
  23. Kriz W, Hahnel B, Hosser H, Ostendorf T, Gaertner S, Kranzlin B, Gretz N, Shimizu F, Floege J. Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis. J Am Soc Nephrol. 2003 Jul;14(7):1904-26.
  24. Ostendorf T, van Roeyen CR, Peterson JD, Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J, Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ, Floege J. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2003 Sep;14(9):2237-47.
  25. Floege J, Eitner F, Van Roeyen C, Ostendorf T. PDGF-D and renal disease: yet another one of those growth factors? J Am Soc Nephrol. 2003 Oct;14(10):2690-1.
  26. Floege J, Grone HJ. [IgA nephropathy: frequent, but rarely diagnosed] Internist (Berl). 2003 Sep;44(9):1131-9.
  27. Steinmetz OM, Panzer U, Harendza S, Mertens PR, Ostendorf T, Floege J, Helmchen U, Stahl RA. No association of the -2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. Nephrol Dial Transplant. 2004 Mar;19(3):596-601.
  28. Floege J. Recurrent IgA nephropathy after renal transplantation. Semin Nephrol. 2004 May;24(3):287-91.
  29. Raffetseder U, Wernert N, Ostendorf T, van Roeyen C, Rauen T, Behrens P, Floege J, Mertens PR. Mesangial cell expression of proto-oncogene Ets-1 during progression of mesangioproliferative glomerulonephritis. Kidney Int. 2004 Aug;66(2):622-32.
  30. Panzer U, Schneider A, Steinmetz OM, Wenzel U, Barth P, Reinking R, Becker JU, Harendza S, Zahner G, Fischereder M, Kramer BK, Schlondorff D, Ostendorf T, Floege J, Helmchen U, Stahl RA. The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int. 2005 Jan;67(1):75-81. Erratum in: Kidney Int. 2005 Mar;67(3):1213.
  31. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005 Jun;16(6):1733-41.
  32. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005 Jun;67(6):2313-20.
  33. van Roeyen CR, Eitner F, Martinkus S, Thieltges SR, Ostendorf T, Bokemeyer D, Luscher B, Luscher-Firzlaff JM, Floege J, Mertens PR. Y-box protein 1 mediates PDGF-B effects in mesangioproliferative glomerular disease. J Am Soc Nephrol. 2005 Oct;16(10):2985-96.
  34. Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol. 2005 Jul-Aug;18(4):354-61.
  35. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frascà GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  36. Floege J. Is mycophenolate mofetil an effective treatment for persistent proteinuria in patients with IgA nephropathy? Nat Clin Pract Nephrol. 2006 Jan;2(1):16-7.
  37. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
  38. Bicanski B, Wenderdel M, Mertens PR, Senderek J, Panzer U, Steinmetz O, Stahl RA, Cerullo G, Diletta Torres D, Schena FP, Zerres K, Floege J. PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. Clin Nephrol. 2007 Feb;67(2):65-72.
  39. Floege J, Eitner F, Barratt J, Smith AC, Feehally J. Mutant mice provide new insight into the role of (mis-)glycation in IgA nephropathy and other glomerular diseases. Nephrol Dial Transplant. 2007 Jun;22(6):1518-20. Epub 2007 Mar 19. Review.
  40. Floege J, Eitner F. Immune modulating therapy for IgA nephropathy: rationale and evidence. Semin Nephrol. 2008 Jan;28(1):38-47. Review.
  41. Eitner F, Floege J. Bacterial protease for the treatment of IgA nephropathy. Nephrol Dial Transplant. 2008 Jul;23(7):2173-5. Epub 2008 Apr 10.
  42. Eitner F, Ackermann D, Hilgers RD, Floege J. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol. 2008 May-Jun;21(3):284-9.
  43. Malycha F, Eggermann T, Hristov M, Schena FP, Mertens PR, Zerres K, Floege J, Eitner F. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant. 2009 Jan;24(1):321-4. Epub 2008 Oct 7.
  44. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A; European IgAN Consortium. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009 Jan-Feb;22(1):152-9.
  45. Boor P, Eitner F, Cohen CD, Lindenmeyer MT; ERCB-Consortium, Mertens PR, Ostendorf T, Floege J. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrol Dial Transplant. 2009 Sep;24(9):2755-62. Epub 2009 Apr 8.
  46. Eitner F, Floege J. Glomerular disease: the Oxford classification--predicting progression of IgAN. Nat Rev Nephrol. 2009 Oct;5(10):557-9.
  47. Barratt J, Eitner F, Feehally J, Floege J. Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time? Nephrol Dial Transplant. 2009 Dec;24(12):3620-3. Epub 2009 Sep 3.
  48. Eitner F, Floege J. Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy? Nat Rev Nephrol. 2010 May;6(5):252-4.
  49. Floege J, Eitner F. Combined immunosuppression in high-risk patients with IgA nephropathy? J Am Soc Nephrol. 2010 Oct;21(10):1604-6. Epub 2010 Sep 9.
  50. Floege J. The Pathogenesis of IgA Nephropathy: What is New and How Does it Change Therapeutic Approaches? Am J Kidney Dis. 2011 Aug 25. [Epub ahead of print]
  51. Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol. 2011 Oct;22(10):1785-94. Epub 2011 Sep 8.
Giovanni Maria Frascà, MD
  1. Vangelista A, Frascà GM, Mondini S, Bonomini V. Idiopathic IgA mesangial nephropathy: immunohistological features. Contrib Nephrol. 1984;40:167-73.
  2. Gharavi AG, Yan Y, Scolari F, Schena FP, Frascà GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  3. Frascà GM, Soverini L, Gharavi AG, Lifton RP, Canova C, Preda P, Vangelista A, Stefoni S.Thin basement membrane disease in patients with familial IgA nephropathy. J Nephrol. 2004 Nov-Dec;17(6):778-85.
  4. Frascà GM, Onetti-Muda A, Mari F, Longo I, Scala E, Pescucci C, Roccatello D, Alpa M, Coppo R, Li Volti G, Feriozzi S, Bergesio F, Schena FP, Renieri A; Italian Renal Immunopathology Group. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant. 2005 Mar;20(3):545-51.
  5. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frascà GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  6. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frascà G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006 May;47(5):761-9.
  7. Schena FP, Cerullo G, Torres DD, Zaza G, Cox S, Bisceglia L, Scolari F, Frascá G, Ghiggeri GM, Amoroso A; European IgA Nephropathy Consortium. Searching for IgA nephropathy candidate genes: genetic studies combined with high throughput innovative investigations. Contrib Nephrol. 2007;157:80-9. Review.
  8. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A; European IgAN Consortium. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009 Jan-Feb;22(1):152-9.
  9. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frascà G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011 Mar 13;43(4):321-7.
Gian Marco Ghiggeri, MD
  1. Gharavi AG, Yan Y, Scolari F, Schena FP, Frascà GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  2. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frascà GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  3. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frascà G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006 May;47(5):761-9.
  4. Schena FP, Cerullo G, Torres DD, Zaza G, Cox S, Bisceglia L, Scolari F, Frascá G, Ghiggeri GM, Amoroso A; European IgA Nephropathy Consortium. Searching for IgA nephropathy candidate genes: genetic studies combined with high throughput innovative investigations. Contrib Nephrol. 2007;157:80-9. Review.
  5. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A; European IgAN Consortium. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009 Jan-Feb;22(1):152-9.
  6. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frascà G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011 Mar 13;43(4):321-7.
  7. Camilla R, Suzuki H, Daprà V, Loiacono E, Peruzzi L, Amore A, Ghiggeri GM, Mazzucco G, Scolari F, Gharavi AG, Appel GB, Troyanov S, Novak J, Julian BA, Coppo R. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011 Aug;6(8):1903-11. Epub 2011 Jul 22.
Francesco Paolo Schena, MD
  1. Schena FP, Mastrolitti G, Fracasso AR, Pastore A, Ladisa N. Increased immunoglobulin-secreting cells in the blood of patients with active idiopathic IgA nephropathy. Clin Nephrol. 1986 Oct;26(4):163-8.
  2. Schena PF, Pastore A, Sinico RA, Montinaro V, Fornasieri A. Polymeric IgA and IgA rheumatoid factor decrease the capacity of serum to solubilize circulating immune complexes in patients with primary IgA nephropathy. J Immunol. 1988 Jul 1;141(1):125-30.
  3. Schena FP, Pastore A, Montinaro V. The role of polymeric IgA in complement-mediated solubilization of IgG and IgA immune complexes. Am J Kidney Dis. 1988 Nov;12(5):433-6.
  4. Manno C, Stella M, Manno M, Fornarelli G, D'Agostino C, Quagliara D, Schena FP. Increased plasma levels of immunoreactive human atrial natriuretic factor in primary IgA nephropathy. Clin Nephrol. 1988 Dec;30(6):308-14.
  5. Antonaci S, Serlenga E, Garofalo AR, Colizzi M, Schena FP. Imbalance of T cell immunoregulatory subsets in primary IgA nephropathy. Cytobios. 1989;59(237):95-100.
  6. Schena FP, Mastrolitti G, Jirillo E, Munno I, Pellegrino N, Fracasso AR, Aventaggiato L. Increased production of interleukin-2 and IL-2 receptor in primary IgA nephropathy. Kidney Int. 1989 Mar;35(3):875-9.
  7. Schena FP, Pastore A, Ludovico N, Sinico RA, Benuzzi S, Montinaro V. Increased serum levels of IgA1-IgG immune complexes and anti-F(ab')2 antibodies in patients with primary IgA nephropathy. Clin Exp Immunol. 1989 Jul;77(1):15-20.
  8. Rifai A, Schena FP, Montinaro V, Mele M, D'Addabbo A, Nitti L, Pezzullo JC. Clearance kinetics and fate of macromolecular IgA in patients with IgA nephropathy Lab Invest. 1989 Oct;61(4):381-8.
  9. Schena FP, Montenegro M, Scivittaro V. Meta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease). Nephrol Dial Transplant. 1990
  10. Wyatt RJ, Rivas ML, Schena FP, Bin JA, Julian BA. Regional variation in C4 phenotype in patients with IgA nephropathy. J Pediatr. 1990 May;116(5):S72-7.
  11. Schena FP.A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990 Aug;89(2):209-15.
  12. Schena FP. [IgA nephropathy. A frequent disease in the Mediterranean area] Recenti Prog Med. 1991 Jun;82(6):338-43
  13. Antonaci S, Polignano A, Ottolenghi A, Tortorella C, Schena FP. Redistribution of natural killer (NK) cell frequency and NK cytotoxic activity in primary IgA nephropathy. Cytobios. 1992;69(276):27-34.
  14. Schena FP, Gesualdo L, Montinaro V. Immunopathological aspects of immunoglobulin A nephropathy and other mesangial proliferative glomerulonephritides. J Am Soc Nephrol. 1992 Apr;2(10 Suppl):S167-72.
  15. Schena FP, Scivittaro V, Ranieri E, Sinico R, Benuzzi S, Di Cillo M, Aventaggiato L. Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy. Clin Exp Immunol. 1993 Apr;92(1):139-44.
  16. Scivittaro V, Gesualdo L, Ranieri E, Marfella C, Schewn SA, Emancipator SN, Schena FP. Profiles of immunoregulatory cytokine production in vitro in patients with IgA nephropathy and their kindred. Clin Exp Immunol. 1994 May;96(2):311-6.
  17. Gesualdo L, Di Paolo S, Milani S, Pinzani M, Grappone C, Ranieri E, Pannarale G, Schena FP. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J Clin Invest. 1994 Jul;94(1):50-8.
  18. Scivittaro V, Ranieri E, Di Cillo M, Aventaggiato L, Emancipator SN, Schena FP. In vitro immunoglobulin production in relatives of patients with IgA nephropathy. Clin Nephrol. 1994 Jul;42(1):1-8.
  19. Ventura MT, Gesualdo L, Capobianco V, Tortorella C, Antonaci S, Schena FP. Effects of in vitro nutrient supplementation on polymorphonuclear cell respiratory burst in primary IgA nephropathy. Clin Nephrol. 1995 Jan;43(1):14-9.
  20. Schena FP. Immunogenetic aspects of primary IgA nephropathy. Kidney Int. 1995 Dec;48(6):1998-2013.
  21. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, Schena FP. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol. 1996 Jun;7(6):906-13.
  22. Ranieri E, Gesualdo L, Petrarulo F, Schena FP. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 1996 Dec;50(6):1990-2001.
  23. Montinaro V, Gesualdo L, Ranieri E, Monno R, Grandaliano G, Schena FP. Renal cortical complement C3 gene expression in IgA nephropathy. J Am Soc Nephrol. 1997 Mar;8(3):415-25.
  24. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant. 1997 Mar;12(3):418-26.
  25. Chen M, Schena FP, Wang SP, Grayston JT, Johnson RJ. Role of chlamydia pneumoniae (TWAR) in IgA nephropathy. Nephron. 1998 Sep;80(1):92.
  26. Gharavi AG, Yan Y, Scolari F, Schena FP, Frascà GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  27. Schena FP. Immunoglobulin a nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists. Am J Med. 2001 Apr 15;110(6):499-500.
  28. Ranieri E, Gesualdo L, Grandaliano G, Maiorano E, Schena FP. The role of alpha-smooth muscle actin and platelet-derived growth factor-beta receptor in the progression of renal damage in human IgA nephropathy. J Nephrol. 2001 Jul-Aug;14(4):253-62.
  29. Manno C, Gesualdo L, D'Altri C, Rossini M, Grandaliano G, Schena FP. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy. J Nephrol. 2001 Jul-Aug;14(4):248-52.
  30. Schena FP, D'Altri C, Cerullo G, Manno C, Gesualdo L. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. Kidney Int. 2001 Aug;60(2):732-40.
  31. Schena FP, Cerullo G, Rossini M, Lanzilotta SG, D'Altri C, Manno C. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol. 2002 Feb;13(2):453-60.
  32. Schena FP. For further investigations in IgA nephropathy the approach from phenotype to genotype is welcome. Clin Exp Immunol. 2002 Mar;127(3):399-401.
  33. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2003;(4):CD003965.
  34. Strippoli GF, Manno C, Schena FP. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis. 2003 Jun;41(6):1129-39.
  35. Grandaliano G, Pontrelli P, Cerullo G, Monno R, Ranieri E, Ursi M, Loverre A, Gesualdo L, Schena FP. Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis. J Am Soc Nephrol. 2003 Aug;14(8):2072-83.
  36. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials.Nephrology (Carlton). 2004 Aug;9(4):177-85.
  37. Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP; Italian Immunopathology Group, Italian Society of Nephrology. The Italian experience of the national registry of renal biopsies. Kidney Int. 2004 Sep;66(3):890-4.
  38. Dal Canton A, Amore A, Barbano G, Coppo R, Emma F, Grandaliano G, Klersy C, Perfumo F, Rizzoni G, Schena FP, Sepe V; Angiotensin Inhibition Mycophenolate mophetil IgA Nephropathy study investigators. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. J Nephrol. 2005 Mar-Apr;18(2):136-40.
  39. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frascà GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  40. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
  41. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frascà G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006 May;47(5):761-9.
  42. Di Duca M, Oleggini R, Sanna-Cherchi S, Pasquali L, Di Donato A, Parodi S, Bertelli R, Caridi G, Frascà G, Cerullo G, Amoroso A, Schena FP, Scolari F, Ghiggeri GM. Cis and trans regulatory elements in NPHS2 promoter: Implications in proteinuria and progression of renal diseases. Kidney Int. 2006 Oct;70(7):1332-41.
  43. Bisceglia L, Cerullo G, Forabosco P, Torres DD, Scolari F, Di Perna M, Foramitti M, Amoroso A, Bertok S, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Ermelinda M, Zelante L, Schena FP; European IgAN Consortium. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006 Dec;79(6):1130-4. Epub 2006 Nov 3.
  44. Bicanski B, Wenderdel M, Mertens PR, Senderek J, Panzer U, Steinmetz O, Stahl RA, Cerullo G, Diletta Torres D, Schena FP, Zerres K, Floege J. PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. Clin Nephrol. 2007 Feb;67(2):65-72.
  45. Schena FP, Cerullo G, Torres DD, Zaza G, Cox S, Bisceglia L, Scolari F, Frascá G, Ghiggeri GM, Amoroso A; European IgA Nephropathy Consortium. Searching for IgA nephropathy candidate genes: genetic studies combined with high throughput innovative investigations. Contrib Nephrol. 2007;157:80-9. Review.
  46. Manno C, Strippoli GF, D'Altri C, Torres D, Rossini M, Schena FP. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007 Jun;49(6):763-75.
  47. Torres DD, Rossini M, Manno C, Mattace-Raso F, D'Altri C, Ranieri E, Pontrelli P, Grandaliano G, Gesualdo L, Schena FP. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2008 Feb;73(3):327-33. Epub 2007 Oct 17
  48. Malycha F, Eggermann T, Hristov M, Schena FP, Mertens PR, Zerres K, Floege J, Eitner F. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant. 2009 Jan;24(1):321-4. Epub 2008 Oct 7.
  49. Strippoli GF, Maione A, Schena FP, Tognoni G, Craig JC. IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice. Am J Kidney Dis. 2009 Jan;53(1):5-8.
  50. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A; European IgAN Consortium. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009 Jan-Feb;22(1):152-9.
  51. Boor P, Eitner F, Cohen CD, Lindenmeyer MT; ERCB-Consortium, Mertens PR, Ostendorf T, Floege J. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrol Dial Transplant. 2009 Sep;24(9):2755-62. Epub 2009 Apr 8.
  52. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009 Sep;76(5):546-56. Epub 2009 Jul 1.
  53. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009 Sep;76(5):534-45. Epub 2009 Jul 1.
  54. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009 Dec;24(12):3694-701. Epub 2009 Jul 23. Erratum in: Nephrol Dial Transplant. 2010 Apr;25(4):1363-4.
  55. Ferrandi M, Cusi D, Molinari I, Del Vecchio L, Barlassina C, Rastaldi MP, Schena FP, Macciardi F, Marcantoni C, Roccatello D, Peters LL, Armelloni S, Min L, Giardino L, Mattinzoli D, Camisasca C, Palazzo F, Manunta P, Ferrari P, Bianchi G. alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy. J Mol Med (Berl). 2010 Feb;88(2):203-17. Epub 2009 Oct 17.
  56. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010 May;77(10):921-7. Epub 2010 Mar 3.
  57. Cox SN, Sallustio F, Serino G, Pontrelli P, Verrienti R, Pesce F, Torres DD, Ancona N, Stifanelli P, Zaza G, Schena FP. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int. 2010 Aug;78(4):396-407. Epub 2010 May 19.
Francesco Scolari, MD
  1. Scolari F, Amoroso A, Savoldi S, Prati E, Scaini P, Manganoni A, Borelli I, Mazzola G, Canale L, Sacchi G, et al. Familial occurrence of primary glomerulonephritis: evidence for a role of genetic factors. Nephrol Dial Transplant. 1992;7(7):587-96.
  2. Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, Viola BF, Nicola B, Movilli E, Sandrini M, Campanini M, Maiorca R. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. 1999 May;33(5):857-65.
  3. Scolari F. Familial IgA nephropathy. J Nephrol. 1999 Jul-Aug;12(4):213-9.
  4. Gharavi AG, Yan Y, Scolari F, Schena FP, Frascà GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  5. Pirulli D, Boniotto M, Vatta L, Crovella S, Spano A, Morgutti M, Zezlina S, Bertola L, Roccatello D, Scolari F, Peruzzi L, Savoldi S, Amoroso A. Polymorphisms in the promoter region and at codon 54 of the MBL2 gene are not associated with IgA nephropathy. Nephrol Dial Transplant. 2001 Apr;16(4):759-64.
  6. Scolari F. Inherited forms of IgA nephropathy. J Nephrol. 2003 Mar-Apr;16(2):317-20.
  7. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frascà GM; European IgA nephropathy Consortium.The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  8. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
  9. Izzi C, Sanna-Cherchi S, Prati E, Belleri R, Remedio A, Tardanico R, Foramitti M, Guerini S, Viola BF, Movilli E, Beerman I, Lifton R, Leone L, Gharavi A, Scolari F. Familial aggregation of primary glomerulonephritis in an Italian population isolate: Valtrompia study.Kidney Int. 2006 Mar;69(6):1033-40.
  10. Bisceglia L, Cerullo G, Forabosco P, Torres DD, Scolari F, Di Perna M, Foramitti M, Amoroso A, Bertok S, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Ermelinda M, Zelante L, Schena FP; European IgAN Consortium. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006 Dec;79(6):1130-4. Epub 2006 Nov 3.
  11. Schena FP, Cerullo G, Torres DD, Zaza G, Cox S, Bisceglia L, Scolari F, Frascá G, Ghiggeri GM, Amoroso A; European IgA Nephropathy Consortium. Searching for IgA nephropathy candidate genes: genetic studies combined with high throughput innovative investigations. Contrib Nephrol. 2007;157:80-9. Review.
  12. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A; European IgAN Consortium. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009 Jan-Feb;22(1):152-9.
  13. Kiryluk K, Gharavi AG, Izzi C, Scolari F. IgA nephropathy--the case for a genetic basis becomes stronger. Nephrol Dial Transplant. 2010 Feb;25(2):336-8. Epub 2009 Nov 13.
  14. Kiryluk K, Julian BA, Wyatt RJ, Scolari F, Zhang H, Novak J, Gharavi AG. Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol. 2010 Nov;25(11):2257-68. Epub 2010 Apr 13.
  15. Camilla R, Suzuki H, Daprà V, Loiacono E, Peruzzi L, Amore A, Ghiggeri GM, Mazzucco G, Scolari F, Gharavi AG, Appel GB, Troyanov S, Novak J, Julian BA, Coppo R. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011 Aug;6(8):1903-11. Epub 2011 Jul 22.
  16. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011 Oct;22(10):1795-803. Epub 2011 Sep 23.